The Efficacy and Safety of 17α-Estradiol (Ell-Cranell® alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study

Androgenetic alopecia is the most common hair loss disorder, affecting both men and women. Initial signs of androgenetic alopecia usually develop during teenage years leading to progressive hair loss with a pattern distribution. Moreover, its frequency increases with age and affects up to 80% Caucasian men and 42% of women. Patients afflicted with androgenetic alopecia may undergo significant impairment of quality of life. The European Dermatology Forum (EDF) initiated a project to develop evidence-based guidelines for the treatment of androgenetic alopecia. Based on a systematic literature research the efficacy of the currently available therapeutic options was assessed and therapeutic recommendations were passed in a consensus conference.The purpose of the guideline is to provide dermatologists with an evidence-based tool for choosing an efficacious and safe therapy for patients with androgenetic alopecia.

show abstract

“…There is no evidence to support the use of topical natural oestrogens, progestogens or anti‐androgens in female AGA (level of evidence 4) …”

Section: Hormonesmentioning

confidence: 99%

Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men – short version

Kanti

Messenger

Dobos

et al. 2017

Acad Dermatol Venereol

238

214

View full text Add to dashboard Cite

show abstract

“…However, 17α-estradiol does not exhibit estrogen activity or exhibit only very weak activity181920. Kim et al21 reported that the hair count and thickness steadily increased after application of topical 17α estradiol when compared with the baseline.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic Efficacy of a Combination Therapy of Topical 17α-Estradiol and Topical Minoxidil on Female Pattern Hair Loss: A Noncomparative, Retrospective Evaluation

et al. 2017

Self Cite

View full text Add to dashboard Cite

BackgroundA variety of agents have been used to treat female pattern hair loss (FPHL), including topical minoxidil, topical 17α-estradiol, oral anti-androgen agents, and mineral supplements. Compared with these single agent regimens, combination therapies could be a better therapeutic option in expectation of superior treatment outcome.ObjectiveThis study was designed to determine the efficacy of a combination therapy consisting of topical 0.025% 17α-estradiol and 3% minoxidil in Korean patients with FPHL.MethodsTherapeutic efficacy was evaluated in 34 women who applied topical 0.025% 17α-estradiol and 3% minoxidil once daily for more than 6 months. Phototrichogram analysis was performed before and after therapy. The efficacy was evaluated with respect to total hair count, hair caliber (as assessed by phototrichogram analysis), and photographic assessment.Results Total hair count and hair caliber both increased from baseline to 6 months in patients treated with the combination therapy of topical 0.025% 17α-estradiol and 3% minoxidil (p<0.001). Photographic assessment also revealed significant disease improvement, thus supporting the therapeutic efficacy.ConclusionA combination therapy consisting of topical 0.025% 17α-estradiol and 3% minoxidil can be tried as an effective treatment for FPHL.

show abstract

“…34 In a clinical trial, topical application of alfatradiol solution exhibited statistically significant increase in number of hair and diameter from baseline; and hair improvement in self-assessment and global photographic assessment compared with placebo treatment. 35 Additionally in a separate clinical study, alfatradiol after topical application showed reduction or stabilization of hair loss.…”

Section: Emerging Agents With Potential In Treatment Of Aga Alfatradiolmentioning

confidence: 99%

Addressing Androgenetic Alopecia-A Complex Disorder-with a Multilateral Treatment Strategy

Patel¹

2017

MOJBB

View full text Add to dashboard Cite

The Efficacy and Safety of 17α-Estradiol (Ell-Cranell® alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study

Cited by 26 publications

References 19 publications

Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men – short version

Evidence‐based (S3) guideline for the treatment of androgenetic alopecia in women and in men – short version

Therapeutic Efficacy of a Combination Therapy of Topical 17α-Estradiol and Topical Minoxidil on Female Pattern Hair Loss: A Noncomparative, Retrospective Evaluation

Addressing Androgenetic Alopecia-A Complex Disorder-with a Multilateral Treatment Strategy

Contact Info

Product

Resources

About